Gerresheimer AG updates 2025 figures as cash flow turns negative. Turnaround plan centers on Centor sale and debt refinancing

By Anna Walker, Analysts & Consensus desk. Reviewed on June 30, 2026 at 3:07 p.m. ET.

Gerresheimer AG (ISIN DE000A0LD6E6) has drawn renewed investor attention after publishing its audited 2025 annual and consolidated financial statements with an unqualified opinion while simultaneously flagging a net loss and negative free cash flow for the year. According to a NewMediaWire release carried by Yahoo Finance, management now expects 2026 revenues in the lower half of its EUR 2.3 to 2.4 billion range and an adjusted EBITDA margin between 17 and 18 percent, signaling a more cautious outlook after a year of governance cleanup.

Audited 2025 results and governance reset

Gerresheimer describes 2025 as a challenging financial year marked by extensive compliance reviews and accounting corrections, but also by the publication of audited financials with an unqualified opinion. The NewMediaWire statement reports that revenues reached about EUR 2.3 billion, supported by portfolio contributions such as the Bormioli Pharma acquisition, while organic growth remained nearly flat. The release on the 2025 statements stresses that the audit opinion was unqualified, a key milestone after prior compliance investigations.

Several secondary reports underline the strain behind these headline numbers. A German-language analysis cites a net loss of about EUR 320 million for 2025, driven largely by impairment charges of more than EUR 500 million and restructuring expenses, and notes that the dividend was suspended for the year. A report on Finanztrends assigns the loss primarily to write-downs and restructuring measures following the balance sheet cleanup.

Cash flow pressure and 2026 guidance cut

The 2025 figures also highlight cash flow pressure that now shapes the 2026 guidance. A detailed summary of the earnings call states that free cash flow before mergers and acquisitions is expected to be negative EUR 50 million to negative EUR 100 million in 2026, a marked shift from earlier expectations of moderate positive cash flow. Call highlights compiled by MarketBeat explain that lower factoring volumes and operational ramp-up costs contribute to this negative outlook.

That same call summary notes that Gerresheimer has reduced its margin ambitions as project delays and efficiency setbacks weighed on performance. For 2026, management now guides to an adjusted EBITDA margin of about 17 to 18 percent, down from an earlier target bandwidth of roughly 18 to 19 percent, while revenues are expected in the lower half of EUR 2.3 to 2.4 billion. An Investing.com transcript adds that management anticipated a drop of 2 to 4 percent in organic revenues, but ultimately delivered slightly positive organic growth of around 0.3 percent, underscoring both resilience and limitation in the underlying business.

Turnaround priorities: Centor sale and refinancing

After resolving governance issues and securing the 2025 audit, Gerresheimer's management has articulated a clear near-term turnaround agenda focused on portfolio and balance sheet actions. The MarketBeat call recap notes that executives now see two top priorities: selling the US-based packaging subsidiary Centor and refinancing debt to stabilize the capital structure. The earnings call highlights describe these steps as essential for addressing high leverage and freeing up resources for operational improvements.

German market coverage adds that an adviser has been mandated for the planned debt refinancing and that Gerresheimer aims to complete the Centor transaction within the current financial year. The Finanztrends article interprets these moves as a response to pressure from negative free cash flow and a sizeable net loss, with the goal of restoring confidence among equity and debt investors.

Representative product: pharmaceutical primary packaging

Beyond the current financial reset, Gerresheimer's core business remains the design and manufacture of primary packaging and drug delivery systems for pharmaceutical and biotech customers. Company descriptions referenced in sector overviews present Gerresheimer as a global partner for pharma, biotech, healthcare and cosmetics, with a broad range of glass and plastic containers, vials, syringes and related devices for injectable and oral medicines. A US-based company directory underscores that these packaging and delivery solutions are critical infrastructure for pharmaceutical supply chains.

Gerresheimer AG stock price snapshot

Gerresheimer AG is listed on Xetra in Germany, and its shares also trade on the US OTC market under the symbol GRRMF. A recent US market report notes that the OTC listing last traded around $30.50, compared with a previous close of $32.10, in relatively thin volume of roughly 100 shares during the session. The Cerbat Gem update adds that the stock had been rated on average as Reduce by analysts tracked on MarketBeat, reflecting ongoing caution about the turnaround path.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.